SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as President Trump's threats of new tariffs on European nations over Greenland escalate geopolitical tensions, leading to a risk-off market sentiment. The community is divided, with some anticipating a significant market pullback, while others view it as a 'buy the dip' opportunity, also noting a Japan-led bond sell-off as a contributing factor. This environment is fueling discussions about broader market volatility and a flight to safe-haven assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following Saudi Arabia's approval of its Anktiva-based Bioshield protocol for non-small cell lung cancer and broader cancer treatment, alongside ongoing discussions with the FDA for papillary bladder cancer. The community is passionately discussing the potential for a significant short squeeze, viewing the company as a disruptive force in oncology while expressing strong frustration with perceived FDA delays.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively trending amid escalating US-EU trade tensions driven by President Trump's tariff threats over Greenland, sparking a widespread market sell-off and global risk-off sentiment. The investment community is sharply divided between those anticipating a deeper correction for technology and growth stocks and fervent "buy the dip" proponents. Immediate market focus remains on an upcoming Supreme Court ruling regarding tariff authority and a heavy week of earnings reports, amplifying uncertainty.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is generating significant buzz following a substantial upward revision to its future revenue outlook and a surging order backlog, further bolstered by a recent large capital raise. The community is actively discussing its promising potential as a rapidly expanding defense and autonomy platform, especially amidst ongoing negotiations for key acquisitions in the critical drone technology sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending amidst intense debate spurred by former President Trump's controversial push for tariffs against European nations, reportedly tied to his interest in Greenland and past grievances. This situation has ignited polarized community discussions concerning potential trade wars and geopolitical repercussions, with many weighing economic stability against his "America First" agenda.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is trending due to a significant surge in natural gas futures, driven by widespread forecasts for severe arctic cold fronts across the US, intensifying heating demand expectations. The community is actively debating the potential for a powerful short squeeze amidst historically high short interest, while also acknowledging the inherent volatility and decay of leveraged natural gas ETFs like $BOIL, often referred to as a "widow maker". Discussions highlight the impact of this weather event on depleting storage levels, yet some remain cautious, pointing to broader warm winter trends and structural factors like contango, questioning the rally's sustainability.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is a major talking point following its J.P. Morgan conference appearance, where investors are eagerly seeking clarity on its strategy for advancing the Matrix-M adjuvant technology and securing new collaborations. Community sentiment is sharply focused on management's pace in realizing pipeline potential, including a recent Pfizer agreement and ongoing Sanofi ventures, with an activist investor's growing stake and significant short interest adding to the intense market watch.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is actively trending amid recent allegations of money laundering and illicit financial ties, triggering a sharp sell-off across the stock. Despite this, community sentiment is divided, with many dismissing the claims as a coordinated short attack ahead of strong earnings, while others are seizing the opportunity to buy into the fundamentally strong AI-powered ad platform.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending after announcing positive data from its placebo-controlled Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing strong efficacy. The community is actively discussing the oral ITK inhibitor's potential in a large market, with many anticipating significant revaluation and partnership opportunities for its novel mechanism of action.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to a significant patent extension for its key products until 2041, coupled with a bullish preliminary business update accelerating IBSRELA's path to $1 billion in revenue by 2029 and multiple analyst price target upgrades. The community is buzzing with renewed acquisition speculation and optimism over the company's long-term value, despite ongoing discussions about short-term price fluctuations attributed to market dynamics. This confluence of positive developments has many viewing Ardelyx as a significantly undervalued biotech with strong commercial execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company posted a net income available to common shareholders of $89.1 million, compared to a net loss of $286.4 million in the third quarter 2024.</li><li>Its revenue also jumped to $277.9 million, compared to $175.4 million in the third quarter 2024.</li><li>The company said strong financial performance in the third quarter was led by the Capital Markets segment.&nbsp;</li></ul>BRC Group Holdings, formerly known as B.Riley Financial, rallied in after-market hours on Wednesday after it announced its delayed quarterly results.&nbsp;The company filed financial reports for three quarters within 120 days, achieving NASDAQ compliance ahead of the deadline, it said in a regulatory filing.&nbsp;<h2 class="st-heading-2">Q3 Results</h2>The company posted a net income available to common shareholders of $89.1 million, compared to a net loss of $286.4 million in the third quarter 2024. The company said basic and diluted earnings per common share were $2.91 compared to a loss per share of $9.39 in the third quarter 2024.Its revenue also jumped to $277.9 million, compared to $175.4 million in the third quarter 2024. The company said strong financial performance in the third quarter was led by the Capital Markets segment with $65.4 million in services and fee revenues, the highest quarterly total since the fourth quarter of 2023.“We are pleased with the third quarter financial results. B. Riley Securities had a very strong quarter across investment banking, advisory, and research and trading with equity and debt capital raises totaling approximately $10.5 billion while delivering product innovation,” Bryant Riley, Chairman and Co-Chief Executive Officer of BRC, said.&nbsp;“Our Communications segment produced strong cash flow, consistent with previous quarters. B. Riley Wealth enhanced products and services for clients, while reducing costs and integrating its back office,” he added.&nbsp;<h2 class="st-heading-2">B.Riley Woes</h2>BRC’s struggles to file timely earnings reports started after a turbulent period in 2024 when it grappled with soured investments, flaws in financial reporting and a U.S. civil investigation.Franchise Group was a key investor of BRC and its bankruptcy in late 2024 left B. Riley burdened with write-offs of hundreds of millions of dollars and it was unable to file its annual and quarterly reports with US regulators on a timely basis. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around RILY trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;One user predicted the stock could hit $15 on Thursday.<a href="https://stocktwits.com/SelectiveTrader/message/641848445">https://stocktwits.com/SelectiveTrader/message/641848445</a>Shares of RILY have jumped 53% over the past year.&nbsp; &nbsp;

Chairman, B. Riley & Co. Bryant Riley (L) and CEO, B. Riley & Co. Tom Kelleher. (Photo by Matt Winkelmeyer/Getty Images)

B.Riley Stock Soars Nearly 40% - What’s Behind The Move?

Company said it has filed its delayed quarterly reports and achieved NASDAQ compliance ahead of the deadline. 

Equity

Company said it has filed its delayed quarterly reports and achieved NASDAQ compliance ahead of the deadline. 


<ul class="summary-bullets"><li>Director Hongyu Zhou purchased 1.1 million company shares, according to an exchange filing on Tuesday.</li><li>Airwa has emerged as a retail favourite – with a 205% increase in Stocktwits watchers over 12 months – after its cryptocurrency pivot last year and its sharp stock moves.</li><li>The nano-cap stock is already up by over 60% in the new year.</li></ul>Shares of Airwa, Inc. (YYAI)&nbsp;soared&nbsp;nearly 16% in after-hours&nbsp;trading on Tuesday, driven by an insider purchase.Hongyu Zhou, a director on the company’s board, purchased 1.1 million shares, bringing his shareholding to 1.6 million shares, according to an exchange filing. The trades were made over Sunday and Monday, with prices per share at $1.23 and $1.41, respectively.The nano-cap stock closed at $1.26 on Tuesday and has risen 61.5% already in the new year.<h2 class="st-heading-2">Emerging Retail Favourite</h2>Airwa is the newest stock garnering attention from retail investors, after the company's pivot to cryptocurrencies late last year.In October, Airwa changed its name from Connexa Sports Technologies and announced&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/Airwa-emerges-as-hottest-talk-of-retai-trader-town/ch6YDj4R3VH">a full pivot</a> to Web3 and blockchain-based financial services, moving away from its earlier business in sports products, such as portable ball launchers and sports analytics.It also announced a joint venture company with JuCoin Capital Pte Ltd, a cryptocurrency exchange and Web3 company headquartered in Dubai, to launch "AiRWA Exchange" for trading tokenized U.S. equities with Solana as a core asset.Before that, the company pursued content creation and partnership deals, including an agreement with TikTok for live-streaming and influencer-driven content in the Middle East and North Africa.Those moves led to an overall 205% increase in&nbsp;<a href="https://stocktwits.com/symbol/YYAI">YYAI</a> watchers on Stocktwits over the last 12 months and a whopping 25,300% increase in message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_at_7_20_15_AM_png_eaeac4e5d6.webp" alt="Screenshot 2026-01-14 at 7.20.15 AM.png" width="701" height="86"><figcaption>YYAI sentiment and message volume as of January 13 | Source: Stocktwits</figcaption></figure>As of late Tuesday, the retail sentiment for the ticker shifted multiple points higher in the ‘extremely bullish’ zone (84/100) over the prior day. “They have crazy 1 billion authorized shares wow. They can issue part of authorized shares whenever they need it. However, director buying shares in open market is always good. Will re- enter after market open tomorrow,” a user&nbsp;<a href="https://stocktwits.com/imraven/message/641731225">remarked</a>.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange during morning trading on January 06, 2026 in New York City. (Photo by Michael M. Santiago/Getty Images)

Why Did YYAI Stock Surge Nearly 16% After-Hours Today?

The new retail favorite jumps after an insider purchase.

<ul class="summary-bullets"><li>The order would also strengthen the company’s position to compete for, and win, larger production opportunities with the army, OSS said.&nbsp;</li><li>In December 2025, OSSwon a $1.2 million production order from Safran Federal Systems.</li><li>In its latest quarterly update, One Stop Systems posted revenues of $18.76, up about 37% from the same period last year.</li></ul>Shares of One Stop Systems Inc. (OSS) have rallied over 50% in the last five days, gaining nearly 30% on Monday. Despite the steep surge, retail investors continue to remain ‘extremely bullish’ on the stock’s performance.Retail optimism comes amid the company’s approximately $1.2 million pre-production order from a U.S. defense prime contractor announced last week. Some investors are touting the potential of multi-year contracts up to $200 million in the U.S. defense and other commercial sectors based on past contracts.<h2 class="st-heading-2">Surge In Orders</h2>On Jan. 7, One Stop Systems said that the company had received a pre-production order from a new U.S. defense prime contractor for the design, development, and delivery of ruggedized integrated compute, and visualization systems for U.S. Army combat vehicles."It also strengthens our position to compete for, and win, larger production opportunities as the Army pursues next-generation vision, sensor distribution and sensor processing technologies across its fleet of manned and unmanned platforms," <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://onestopsystems.com/blogs/press-releases/oss-announces-new-partnership-with-leading-u-s-defense-prime-to-develop-enhanced-integrated-vision-system-for-u-s-army">said</a> Mike Knowles, President and CEO of One Stop Systems.In December 2025, the company won a $1.2 million production order from Safran Federal Systems, which brought the aggregate order value to about $1.9 million with the company following a September 2025 order, OSS said at the time.The company also sold all its assets and operations of Bressner Technology GmbH in December 2025 for $22.4 million. OSS had acquired Bressner in October 2018 for about $5.6 million.In its latest quarterly update, One Stop Systems posted revenues of $18.76, up about 37% from the $13.7 million in the same period last year. The company also posted earnings per share of $0.01 compared to a loss per share of $0.32 in the same period last year.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OSS">OSS stock</a> was in ‘extremely bullish’ territory over the past day amid ‘extremely high’ message volumes.One bullish user noted the U.S. Army’s potential funding for a rugged 360-degree Situational Awareness system, anticipating that this could lead to over $200 million in orders for the company over the next three to five years.<stembedurl>https://stocktwits.com/DisneyTrader/message/641562227</stembedurl>&nbsp;Another user called OSS an ‘under the radar’ AI stock that has been left behind.<stembedurl>https://stocktwits.com/RetireQuick/message/641566304</stembedurl>&nbsp;A third user forecasted that the stock’s price could go to $20.<stembedurl>https://stocktwits.com/GoChiefs15/message/641571302</stembedurl>&nbsp;Shares of OSS have gained over 239% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the One Stop Systems (OSS) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OSS Stock Rallied Over 50% In The Last 5 Days — Why Is Retail Still Bullish?

Retail optimism for One Stop Systems comes amid the company’s about $1.2 million pre-production order from a U.S. defense prime contractor announced last week.

<ul class="summary-bullets"><li>This is the second time that the FDA has refused to approve EBVALLO.</li><li>Atara said in a statement on Monday that the FDA’s new position is “contrary” to its prior alignment with the company on the trial design.</li><li>Atara had transferred its application seeking approval for EBVALLO to a U.S. pharma unit of Pierre Fabre Laboratories in November.</li></ul>Shares of Atara Biotherapeutics, Inc. (ATRA) slumped 53% on Monday after the U.S. Food and Drug Administration refused approval for its immunotherapy EBVALLO in treating patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease.Epstein-Barr Virus (EBV)-positive Post-Transplant Lymphoproliferative Disorder (PTLD) is a serious, often life-threatening complication after organ or stem cell transplantation, characterized by uncontrolled growth of EBV-infected B-cells due to suppressed immunity, ranging from mononucleosis-like illness to aggressive lymphoma.The FDA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business">said</a> in a letter to the company that it is unable to approve its EBVALLO application in present form, stating that the trial conducted by the company is not adequate to provide evidence of effectiveness for accelerated approval. The authority also stated that the trial’s interpretability is confounded due to trial study design, conduct, and analysis.<h2 class="st-heading-2">Back-To-Back Rejection</h2>This is the second time that the FDA has refused to approve EBVALLO. The company resubmitted its application in 2025 after it was rejected the first time due to a concern with manufacturing.Atara said in a statement on Monday that the FDA’s new position is “contrary” to its prior alignment with the company on the trial design. “This prior alignment had been reached by Atara and the FDA through multiple, documented meetings held over the past five plus years,” it said. &nbsp;Atara had transferred its application seeking approval for EBVALLO to a U.S. pharma unit of Pierre Fabre Laboratories in November. Pierre will now seek a meeting with the FDA, which is expected to be granted within 45 days. The company said that it intends to urgently interact with FDA to find a path forward for EBVALLO approval with Pierre.<h2 class="st-heading-2">Company’s Reaction</h2>Atara CEO Cokey Nguyen said that the company is “surprised and disappointed” by the FDA decision.“The issues highlighted in the CRL were issues Atara and the FDA aligned on in previous reviews or communications. We had aligned with the agency to accept an Accelerated Approval and to perform a post marketing confirmatory study to support full approval. We proceeded with the BLA submission on this basis and continued all remediation efforts after the resubmission in 2025, in full reliance of the confirmation provided by the FDA,” the CEO said.Atara ended 2025 with cash, cash equivalents and short-term investments of $8.5 million after trimming down workforce by about 90% year-over-year and transitioning almost all activities and costs pertaining to EBVALLO to Pierre Fabre laboratories.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATRA stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed disappointment over the news.<stembedurl>https://www.stocktwits.com/BwesY/message/641538764</stembedurl>Yet another said that they added more shares of the company. “I am already sensing a big fight back,” they said.<stembedurl>https://www.stocktwits.com/Niddi/message/641533765</stembedurl><a href="https://stocktwits.com/symbol/ATRA">ATRA stock</a> has dropped 60% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-planet-labs-stock-gain-today/cmUad7cR4Ej">Planet Labs Stock Gained 7% Today — What Is The Swedish Military Deal About?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’

The Food and Drug Administration said in a letter to the company that it is unable to approve its EBVALLO application in present form, citing inadequate evidence of effectiveness for accelerated approval.

<ul class="summary-bullets"><li>Anaphylm is Aquestive’s sublingual epinephrine film for allergic reactions.</li><li>The Anaphylm application is supported by 11 clinical studies involving 411 subjects, the company said.</li><li>Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA date on January 31, it added.</li></ul>Shares of Aquestive Therapeutics (AQST) plunged 40% in pre-market trading on Friday after the company announced that it received a letter from the U.S. Food and Drug Administration (FDA) identifying deficiencies that currently prevent labeling discussions on Anaphylm.Anaphylm is Aquestive’s sublingual (under the tongue) epinephrine film for allergic reactions.However, the FDA also confirmed its review of the New Drug Application (NDA) remains ongoing, and no final decision has been made.Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA (Prescription Drug User Fee Act) date on January 31, noting that delays in receiving details could impact the approval timeline. A PDUFA date is the FDA's target date to make a decision on a drug application.The Anaphylm application is supported by 11 clinical studies involving 411 subjects, demonstrating pharmacokinetics comparable to epinephrine auto-injectors and a similar safety profile, Aquestive added.“As part of its ongoing review of the Company’s NDA for Anaphylm, the FDA notified us that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time. Although the notification did not specify the deficiencies, Aquestive is working to understand and resolve the concerns. The FDA stated that the notification does not reflect a final decision on the pending application and the FDA’s review remains ongoing,” said Dan Barber, President and Chief Executive Officer of Aquestive.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the strong intraday decline, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/AQST">AQST</a> turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_2de986106b.webp" alt="AQST.jpg">Over the past year, the stock has gained 23%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Plug Power said it was impacted by the speed and development of hydrogen economy.

Why Did AQST Stock Plunge 40% In Pre-Market Today?

The company said the U.S. FDA identified deficiencies that prevent labeling discussions for a drug to treat allergic reactions.

AQST Stock Plunges On An FDA Setback For Its Allergy Drug – Here’s What Has Changed 

<ul class="summary-bullets"><li>Cineverse expects Giant Worldwide to contribute pro forma core profit of $3.5 million -$4 million in fiscal year 2027.</li><li>Cineverse did not disclose the value of the all-cash deal.&nbsp;</li><li>Cineverse on Tuesday announced that streaming rights to The Toxic Avenger have been acquired by Hulu.&nbsp;</li></ul>Cineverse shares were in the spotlight on Wednesday after it said it is acquiring Giant Worldwide in an all-cash deal, a day after Hulu acquired streaming rights from Cineverse for the Toxic Avenger.&nbsp;The transaction adds a substantial base of recurring revenue from major entertainment companies to Cineverse's Matchpoint platform, the company said in a statement. The company did not disclose the value of the deal.<h2 class="st-heading-2">Financial Implications Of Deal</h2>Cineverse expects Giant Worldwide to contribute pro forma revenue of $15 million-17 million and pro forma Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $3.5 million-$4 million in fiscal year 2027. Within the first year the company anticipates approximately $2.5 million in additional annualized synergies through integration with Matchpoint."We are immediately adding a significant base of prestigious Hollywood studio relationships by combining Giant Worldwide's long-standing client relationships with Matchpoint's advanced AI-native infrastructure,” said Tony Huidor, President of Technology and Chief Product Officer at Cineverse.Cineverse on Tuesday announced that streaming rights to The Toxic Avenger have been acquired by Hulu. The film's Subscription Video on Demand (SVOD) premiere will be on Thursday, January 8, 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around CNVS trended in the ‘bullish’ territory amid ‘high’ message volume.One user said that 2026 is the year for Cineverse to show progress in all verticals, adding that ‘the pieces are there’. “The discount exists because management hasn’t executed yet,” they wrote.&nbsp;<stembedurl>https://stocktwits.com/TFars/message/641110603</stembedurl>Another user said that Cineverse is quietly assembling the distribution and monetization stack required to operate as a scalable media platform. The user further added that Giant Worldwide fits that strategy perfectly.<stembedurl>https://stocktwits.com/FinSUN/message/641092417</stembedurl>Shares of Cineverse have fallen more than 42% over the past year.&nbsp; &nbsp;

 Peter Dinklage, Taylour Paige, Elijah Wood and Jacob Tremblay attend the 2025 Comic-Con International: San Diego - Premiere Of Cineverse's "The Toxic Avenger".

Cineverse Jumps After Announcing Acquisition Of Giant Worldwide — Retail Says Deal Fits Company Strategy ‘Perfectly’

Cineverse expects Giant Worldwide to contribute pro forma revenue of $15 million-17 million in fiscal year 2027.

Cineverse expects Giant Worldwide to contribute pro forma revenue of $15 million -17 million in fiscal year 2027.


<ul class="summary-bullets"><li>Nutriband’s shareholders will retain a 10% shareholding in Earth Vision Bio.</li><li>The firm will use the proceeds from the sale of Pocono Pharma to continue developing AVERSA Fentanyl.</li><li>It expects annual U.S. sales from AVERSA Fentanyl to reach $80 million to $200 million.</li></ul>Shares of Nutriband Inc. (<a href="https://stocktwits.com/symbol/NTRB">NTRB</a>) surged more than 18% on Monday after the company announced an agreement to sell 90% stake in its subsidiary, Pocono Pharmaceutical, to EarthVision Bio for $5 million.Nutriband’s shareholders will retain a 10% shareholding in Earth Vision Bio following the acquisition, it stated.Nutriband will use the proceeds from the sale of Pocono Pharma towards its continued development of AVERSA Fentanyl. The company develops transdermal drug delivery systems that are focused on preventing abuse and misuse of medications like opioids using its proprietary AVERSA Technology.<h2 class="st-heading-2">Bet On Abuse-Deterrent Aversa Fentanyl</h2>The U.S. government has been cracking down on illicit fentanyl. U.S. President Donald Trump earlier this month signed an executive order designating it as a weapon of mass destruction and recognizing the substance as a direct threat to U.S. national security.Nutriband’s AVERSA Fentanyl uses its abuse-deterrent technology, which is designed to improve the safety profile of transdermal drugs that are susceptible to abuse, such as fentanyl, while making sure these drugs remain accessible to patients who need them.Nutriband has been partnering with Kindeva Drug Delivery to develop AVERSA Fentanyl, which combines Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. It expects annual U.S. sales from AVERSA Fentanyl to reach $80 million to $200 million.Nutriband had signed a non-binding Letter of Intent (LOI) with Qvanta Group of Companies to explore potential collaboration areas, including secure AI and analytics platforms for regulated pharmaceutical data, and cybersecurity that support abuse-deterrent technologies.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around NTRB trended in “extremely bullish” territory amid “high” message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:639/68;" src="https://news.stocktwits-cdn.com/ntrb_PNG_d487765902.webp" alt="Retail sentiment around NTRB trended in “extremely bullish” territory amid “high” message volumes. " width="639" height="68"></figure>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena. (Photo by Sarah Reingewirtz/MediaNews Group/Los Angeles Daily News via Getty Images)

What’s Driving Nutriband Shares Higher Today?

Nutriband has agreed to sell 90% of its stake in its subsidiary Pocono Pharmaceuticals for $5 million. 

<ul class="summary-bullets"><li>Following the written FDA response, the company believes there is alignment with the agency on the proposed patient population for enrollment in its registration trial.</li><li>The company also plans to pursue another follow-up meeting to finalize details on the next clinical trial design that were not fully resolved in the written response. &nbsp;</li><li>Galectin Therapeutics also secured a $10 million line of credit from its chairman that would cover its expenditures until at least March 2027.</li></ul>Galectin Therapeutics Inc. (<a href="https://stocktwits.com/symbol/GALT">GALT</a>) shares plunged more than 30% in Friday morning trading after the company announced it had received feedback from the U.S. Food and Drug Administration (FDA) on its belapectin drug. The pharma company also announced a new $10 million line of credit.The company said that the FDA provided a written response to its Type C meeting—a non-urgent, non-milestone meeting—request regarding the development of belapectin, its investigational galectin-3 inhibitor for patients with MASH cirrhosis and portal hypertension.The FDA feedback has led Galectin Therapeutics to believe that there is alignment with the agency on the patient population proposed for enrollment in a registration trial.Separately, the company announced that its chairman, Richard E. Uihlein, will provide a $10 million unsecured, convertible line of credit financing.<h2 class="st-heading-2">FDA Clarification</h2>Galectin Therapeutics had requested an in-person or teleconference meeting with the FDA to address its queries regarding the development of belapectin. However, the FDA converted its initial request for a meeting to a written response.The company now plans to pursue another follow-up Type C meeting to finalize details on the next clinical trial design that were not fully resolved in the written response, it said. &nbsp;Galectin Therapeutics believes the meeting will provide an opportunity to clarify recent biomarker data that were not added to the initial submission ,and said that the next FDA interaction would be important to gain full clarity to advance belapectin towards the next Phase 3 clinical trial.<h2 class="st-heading-2">Line Of Credit</h2>The $10 million unsecured, convertible line of credit from the company’s chairman, along with its cash reserves, would fund Galectin Therapeutics’ expenditures until at least March 2027, it said. The maturity dates of all convertible lines of credit and convertible notes payable to its chairman have been extended through June 30, 2027.“This additional financing will enable us to continue to explore multiple strategies for the advancement of belapectin. We will provide updates as they become available,” Joel Lewis, Chief Executive Officer at Galectin Therapeutics, said.“Our focus remains on advancing belapectin for patients with MASH cirrhosis and portal hypertension,” he added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around Galectin Therapeutics remained in the ‘bullish’ territory over the past 24 hours, and message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1263/161;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_19_at_8_42_09_PM_png_3dac2150a5.webp" alt="On Stocktwits, the retail sentiment around Galectin Therapeutics remained in the ‘bullish’ territory over the past 24 hours, and message volume stayed at ‘high’ levels." width="1263" height="161"></figure>GALT was among the top trending tickers on Stocktwits at the time of writing.One user highlighted their bullish stance on GALT stock, stating that more clarity would come after the in-person FDA meeting.<stembedurl>https://stocktwits.com/skylightmoon/message/639688546</stembedurl>Shares of GALT are up over 263% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did GALT Shares Plummet Over 30% Today?

Galectin Therapeutics said it had received feedback from the FDA on its belapectin drug and also announced a new $10 million line of credit. 

<ul class="summary-bullets"><li>FueCell's fourth-quarter earnings received a boost from strong demand for electricity amidst the global AI push.</li><li>The company’s fourth-quarter revenue surged past estimates.</li><li>It reported a narrower loss in the quarter compared to the year-ago period.</li></ul>FuelCell Energy (<a href="https://stocktwits.com/symbol/FCEL">FCEL</a>) shares jumped 35% at the opening bell on Thursday after its fourth quarter revenue surged past analyst estimates, helped by increasing demand for electricity and data center projects amidst a global AI push, while its loss came in narrower than expected.&nbsp;As corporations and governments continue to adopt and implement artificial intelligence in their daily operations, the demand for data centers and electricity to keep them running has remained high, helping firms like FuelCell, which provide fuel cell power plants that generate clean electricity for businesses and communities.<h2 class="st-heading-2">&nbsp; Q4 Report</h2>The company reported fourth-quarter (Q4) revenue of $55 million, well above analyst estimates of $47.2 million, according to data from Fiscal.ai.&nbsp;“We believe that our fourth quarter performance and ongoing cost reductions have positioned us well to meet the accelerating demand for electricity and data center projects in the U.S. and internationally,” said Jason Few, President and CEO of FuelCell Energy.The company also posted an adjusted net loss attributable to common stockholders of $29.8 million in the quarter, compared to an adjusted net loss of $35.3 million in the fourth quarter of fiscal 2024. It reported an adjusted net loss per share of $0.83 compared to analysts’ expectation of a loss of $1.09 per share.&nbsp;<h2 class="st-heading-2"> How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around FCEL remained in ‘extremely bullish’ territory, and message volume remained ‘extremely high’. The stock is among the top 10 trending tickers on Stocktwits.&nbsp;<figure class="image"><img style="aspect-ratio:636/76;" src="https://news.stocktwits-cdn.com/Capture_3_PNG_f220001d6f.webp" alt="On Stocktwits, the retail sentiment around FCEL remained in ‘extremely bullish’ territory, and message volume remained ‘extremely high’. " width="636" height="76"></figure>One of the users on Stocktwits sounded “super bullish” on the stock after its earnings report.<figure class="image"><img style="aspect-ratio:648/109;" src="https://news.stocktwits-cdn.com/Capture2_PNG_cf56df1028.webp" alt="One of the users on Stocktwits sounded “super bullish” on the stock after FuelCell's earnings report." width="648" height="109"></figure>FuelCell Energy shares have declined nearly 24% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp; &nbsp;

In this photo illustration, the FuelCell Energy logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did FuelCell Stock Rocket 35% Today?

The company reported fourth-quarter revenue of $55 million, well above analyst estimates of $47.2 million, according to data from Fiscal.ai. 

<ul class="summary-bullets"><li>AXIL’s hearing products will hit over 3,700 Walmart stores, marking its largest single retail placement ever.&nbsp;</li><li>AXIL already has partnerships with Costco’s 300-plus retail and online stores.&nbsp;</li><li>Shares of AXIL are up over 30% in the last year.&nbsp;</li></ul>AXIL Brands, Inc. (AXIL) shares soared in Thursday’s premarket trade after the company announced a national retail distribution agreement with Walmart, which will bring its hearing protection and enhancement products to a massive new audience.The company said that under the agreement, AXIL's products, including its new AXIL® X30 LT earplugs, would be available in over 3,700 Walmart stores.&nbsp;According to the statement, the Walmart rollout represents the firm’s largest single retail placement to date.Shares of AXIL soared over 150% on the announcement.&nbsp;<h2 class="st-heading-2">New Horizons</h2>AXIL’s debut at Walmart is slated for February 2026, with the launch of a new product, the AXIL® X30 LT in-ear hearing protection plugs, available in retail outlets.In September this year, AXIL&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://goaxil.com/blogs/press-releases/axil-brands-launches-nationwide-at-costco-with-axil-xcor-se-advanced-hearing-protection-and-enhancement-earbuds">partnered with Costco</a> to take its earbuds to over 300 stores in the U.S. and eventually expanded to offer them on Costco’s online platform as well.&nbsp;Between Walmart and Costco placements, Axil’s expansion gives it access to millions of American consumers. In the latest statement, the company said that these partnerships position it for faster growth and greater brand visibility starting in 2026.“This partnership is a testament to the performance, value, and consumer demand for our products and will make our best-in-class hearing protection and enhancement technology available to millions of consumers who shop at Walmart every day,” Jeff Toghraie, Chairman and CEO at AXIL Brands, said.&nbsp;In October, <a href="https://stocktwits.com/symbol/AXIL">AXIL</a> announced its first-quarter (Q1) 2026 results, reporting a 17.2% increase in quarterly sales and an improvement in operating income of $0.4 million, compared to an operating loss in the same period last year.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AXIL jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped to ‘extremely high’ levels at the time of writing.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_5_03_15_PM_png_87987f7875.webp" alt="Screenshot 2025-12-11 at 5.03.15 PM.png">One user stressed their bullish outlook on the stock.&nbsp;<stembedurl>https://stocktwits.com/nader_1/message/638834530</stembedurl>Shares of AXIL are up over 30% in the last year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

The exterior of a Walmart store in Hollywood, Florida. (Photo by Joe Raedle/Getty Images)

 AXIL Stock Just Rocketed Over 150% Today — What’s The Walmart Angle? 

AXIL Brands announced a partnership with Walmart that would bring its products to the stores of America’s largest retailer.

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWC News

IWCiShares Micro-Cap ETF